We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 105.90 | 3 | 11:03:19 |
From May 2019 to May 2024
Piramal Healthcare Ltd. (500302.BY) said Friday its founders have agreed not to make generic drugs to sell in India for a period of eight years as part of the company's deal to sell its India-branded generic drugs business to Abbott Laboratories (ABT).
Earlier in the day, Piramal Healthcare agreed to sell the business to Abbott Laboratories (ABT) for about $3.72 billion.
The start of the eight-year period will begin the date the deal closes, which is expected in the second half of 2010.
The founders will not engage in the manufacture and sale of these products in emerging markets either, the Indian pharmaceutical maker said in a statement.
By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
